PHO and OSAKA Related Headlines
Go Back- Photocure and Artera to partner on digital pathology AI test evaluation for Bladder Cancer
- Photocure acquires Vesica Health for $30.5 million in bladder cancer deal
- Photocure ASA to Acquire Vesica Health Inc., Strengthening Leadership in Bladder Cancer Diagnostics
- AUA 2026: new studies demonstrated Blue Light Cystoscopy benefits in high-risk NMIBC management and cost comparison study
- Photocure ASA: Results for the first quarter of 2026
- New health economic methodology published: comparing cost-effectiveness of BLC versus NBI imaging technology in bladder cancer
- Photocure ASA: Update on Regulatory Classification for OAY Equipment
- Photocure: Trials in Progress presented at the European Association of Urology (EAU) 2026 congress aim to enable a more personalized bladder cancer care pathway
- Asieris: CEVIRA Approved in China as First-in-Class Non-Invasive Therapy for Cervical Precancerous Lesions
- Photocure ASA: Results for the fourth quarter of 2025
- The impact of avoiding recurrence: New BRAVO Study abstract at SUO 2025 demonstrates Cost Neutrality in Blue Light versus White Light Cystoscopy comparison
- Photocure ASA: Results for the third quarter of 2025
- Photocure and Intelligent Scopes Corporation partner on development of AI for blue light cystoscopy
- Photocure ASA: Results for the second quarter of 2025
PHO and OSAKA Related Press Releases
Go Back- Photocure and Artera to partner on digital pathology AI test evaluation for Bladder Cancer
- Photocure ASA to Acquire Vesica Health Inc., Strengthening Leadership in Bladder Cancer Diagnostics
- AUA 2026: new studies demonstrated Blue Light Cystoscopy benefits in high-risk NMIBC management and cost comparison study
- Photocure ASA: Results for the first quarter of 2026
- New health economic methodology published: comparing cost-effectiveness of BLC versus NBI imaging technology in bladder cancer
- Photocure ASA: Update on Regulatory Classification for OAY Equipment
- Photocure: Trials in Progress presented at the European Association of Urology (EAU) 2026 congress aim to enable a more personalized bladder cancer care pathway
- Asieris: CEVIRA Approved in China as First-in-Class Non-Invasive Therapy for Cervical Precancerous Lesions
- Photocure ASA: Results for the fourth quarter of 2025
- The impact of avoiding recurrence: New BRAVO Study abstract at SUO 2025 demonstrates Cost Neutrality in Blue Light versus White Light Cystoscopy comparison
- Photocure ASA: Results for the third quarter of 2025
- Photocure and Intelligent Scopes Corporation partner on development of AI for blue light cystoscopy
- Photocure ASA: Results for the second quarter of 2025
